• Currency:
0

Thymosin Alpha 1 10mg

£44.00
  • Ex Tax:£36.67
  • Thymosin Alpha 1 (Ta1)


    Synonym: Ac-Ser-Asp-Ala-Ala-Val-Asp-Thr-Ser-Ser-Glu-Ile-Thr-Thr-Lys-Asp-Leu-Lys-Glu-Lys-Lys-Glu-Val-Val-Glu-Glu-Ala-Glu-Asn


    It was the first of the peptides from Thymosin Fraction 5 to be completely sequenced and synthesized. Unlike β thymosins, to which it is genetically and chemically unrelated, thymosin α1 is produced as a 28-amino acid fragment, from a longer, 113-amino acid precursor, prothymosin α.[2]

    Thymosin α1 is believed to be a major component of Thymosin Fraction 5 responsible for the activity of that preparation in restoring immune function in animals lacking thymus glands. It has been found to enhance cell-mediated immunity in humans as well as experimental animals.[3]


    A 28 amino acid sequence peptide, first isolated in 1977. It is derived from prothymosin alpha, a protein that in humans is encoded by the PTMA gene. [1]. and is produced by stromal cells in the human Thymus.

    It was the first of the peptides from Thymosin Fraction 5 to be completely sequenced and synthesized. Unlike β thymosins, to which it is genetically and chemically unrelated, thymosin α1 is produced as a 28-amino acid fragment, from a longer, 113-amino acid precursor, prothymosin α.[2]

    Ta1 is believed to be a major component of Thymosin Fraction 5 responsible for the activity of that preparation in restoring immune function in animals lacking thymus glands. It has been found to enhance cell-mediated immunity in humans as well as experimental animals.[3]

    Ta1 has been shown to augment host immune defence capabilities by 2 mechanisms. Firstly by increasing the number of T cells (A Tcell is a type of immune cell that plays a central role in immune system defence) and secondly by restoring Tcell antibody production. Ta1 has also been shown to reduce pain associated with inflammation.


    Summary: More immune cells with greater functional capacity.


    Peer reviewed papers:

    Thymosin alpha 1: biological activities, applications and genetic engineering production

    Juan Li et. al

    Peptides, 31(11), undefined (2010-8-12)

    Thymosin alpha 1 (Tα1), a 28-amino acid peptide, was first described and characterized from calf thymuses in 1977. This peptide can enhance T-cell, dendritic cell (DC) and antibody responses, modulate cytokines and chemokines production and block ste...Read More


    Thymosin alpha-1; a natural peptide inhibits cellular proliferation, cell migration, the level of reactive oxygen species and promotes the activity of antioxidant enzymes in human lung epithelial adenocarcinoma cell line (A549).

    Kharazmi-Khorassani J, Asoodeh A.

    Environ Toxicol. 2019 Aug;34(8):941-949. doi: 10.1002/tox.22765. Epub 2019 May 8.

    PMID: 31067016

     

    Neurosci Bull. 2019 Aug;35(4):637-648. doi: 10.1007/s12264-019-00346-z. Epub 2019 Feb 21.

    Thymosin Alpha-1 Inhibits Complete Freund's Adjuvant-Induced Pain and Production of Microglia-Mediated Pro-inflammatory Cytokines in Spinal Cord.

    Xu Y1, Jiang Y2, Wang L3, Huang J4, Wen J5, Lv H3, Wu X3, Wan C3, Yu C3, Zhang W3, Zhao J3, Zhou Y3, Chen Y6

     

    Stability:

    Store lyophilized protein at -20 °C. Aliquot the product after reconstitution to avoid repeated freezing/thawing cycles. Reconstituted protein can be stored at 4 °C for a limited period of time. The lyophilized protein remains stable until the expiry date when stored at -20 °C.

    Source: Biosynthesis

    Usage: 

    Product is prepared for LABORATORY RESEARCH USE ONLY. The product may not be used for other purposes.

    References:

    1.  Manrow RE, Leone A, Krug MS, Eschenfeldt WH, Berger SL (Jul 1992). "The human prothymosin alpha gene family contains several processed pseudogenes lacking deleterious lesions"Genomics13 (2): 319–31. doi:10.1016/0888-7543(92)90248-QPMID 1612591.
    2. ^ Garaci E (September 2007). "Thymosin alpha1: a historical overview". Ann. N. Y. Acad. Sci1112: 14–20. doi:10.1196/annals.1415.039PMID 17567941.
    3. ^ Wara DW, Goldstein AL, Doyle NE, Ammann AJ (January 1975). "Thymosin activity in patients with cellular immunodeficiency". N. Engl. J. Med292 (2): 70–4. doi:10.1056/NEJM197501092920204PMID 1078552.



    Write a review

    Please login or register to review